IASO BIO to Start Trials of CAR-T in Leukemia Patients
June 03, 2021 at 06:50 AM EDT
Nanjing IASO Bio has been approved to start China clinical trials of CT120, its second CAR-T candidate to enter clinical trials. The company will test its fully human CD19/CD22 dual-targeting chimeric antigen receptor-T cell therapy in patients with relapsed/refractory B-acute lymphoblastic leukemia. Two years ago, IASO and its partner, Suzhou Innovent, started a Phase Ib/II trial of their jointly developed lentiviral vector/CAR-T candidate, which is designed to treat multiple myeloma patients who have progressed after an earlier CAR-T treatment. More details.... Stock Symbol: (HK: 01801) Share this with colleagues: // //
